• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>International heart journal >Atorvastatin-induced changes in plasma coenzyme q10 and brain natriuretic peptide in patients with coronary artery disease.
【24h】

Atorvastatin-induced changes in plasma coenzyme q10 and brain natriuretic peptide in patients with coronary artery disease.

机译：阿托伐他汀诱导冠心病患者血浆辅酶q10和脑钠肽的变化。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The beneficial effects of statins in patients with coronary artery disease (CAD) may be balanced by concerns that statins can depress production of ubiquinone (CoQ10), which serves as a component of mitochondrial energy production and an antioxidant. Accordingly, the effects of atorvastatin (ATO)-induced changes in plasma CoQ10 on BNP and oxidative stress were investigated. In 29 patients with CAD, the plasma levels of CoQ10 and BNP and urinary excretion of 8-iso-prostaglandin F2alpha (8-iso-PGF) were determined before and after 3-month treatment with ATO. Ten patients had received pravastatin and 10 patients fluvastatin, while 9 patients had not received any statin before ATO. There was a linear correlation between ATO-induced changes in total cholesterol and CoQ10 (r = 0.632, P < 0.01), and an inverse correlation between ATO-induced changes in CoQ10 and BNP (r = -0.497, P < 0.01). There was no significant correlation between ATO-induced changes in CoQ10 and 8-iso-PGF. Multivariate analysis revealed that ATO-induced decreases in plasma CoQ10 were significantly associated with increasing BNP levels. In conclusion, long-term treatment with ATO might increase plasma levels of BNP in patients with CAD when it is accompanied by a greater reduction in plasma CoQ10. However, ATO-induced decreases in CoQ10 might not increase oxidative stress.
机译：他汀类药物对冠状动脉疾病（CAD）患者的有益作用可能会因担心他汀类药物会抑制泛醌（CoQ10）的产生而受到影响，泛醌（CoQ10）是线粒体能量产生的成分和抗氧化剂。因此，研究了阿托伐他汀（ATO）诱导的血浆辅酶Q10的变化对BNP和氧化应激的影响。在29例CAD患者中，在接受ATO治疗3个月之前和之后测定了血浆CoQ10和BNP水平以及8-异前列腺素F2α（8-异PGF）的尿排泄。 10例患者接受普伐他汀和10例氟伐他汀，而9例患者在ATO之前未接受任何他汀类药物。 ATO诱导的总胆固醇和辅酶Q10的变化之间存在线性关系（r = 0.632，P <0.01），而ATO诱导的辅酶Q10和BNP的变化之间呈负相关（r = -0.497，P <0.01）。 ATO诱导的CoQ10和8-iso-PGF的变化之间无显着相关性。多变量分析显示，ATO诱导血浆CoQ10下降与BNP水平升高显着相关。综上所述，长期使用ATO治疗可能会增加CAD患者血浆CoQ10的下降，从而增加其血浆BNP的水平。但是，ATO引起的辅酶Q10降低可能不会增加氧化应激。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号